Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

SHP2 tyrosine phosphatase stimulates CEBPA gene expression to mediate cytokine-dependent granulopoiesis.

Zhang L, Friedman AD.

Blood. 2011 Aug 25;118(8):2266-74. doi: 10.1182/blood-2011-01-331157. Epub 2011 Jul 1.

2.

Differential biological activity of disease-associated JAK2 mutants.

Zou H, Yan D, Mohi G.

FEBS Lett. 2011 Apr 6;585(7):1007-13. doi: 10.1016/j.febslet.2011.02.032. Epub 2011 Mar 4.

3.

Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.

Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM, Silverman MH, Gilliland DG, Shorr J, Tefferi A.

J Clin Oncol. 2011 Mar 1;29(7):789-96. doi: 10.1200/JCO.2010.32.8021. Epub 2011 Jan 10.

4.

Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells.

Mullally A, Lane SW, Ball B, Megerdichian C, Okabe R, Al-Shahrour F, Paktinat M, Haydu JE, Housman E, Lord AM, Wernig G, Kharas MG, Mercher T, Kutok JL, Gilliland DG, Ebert BL.

Cancer Cell. 2010 Jun 15;17(6):584-96. doi: 10.1016/j.ccr.2010.05.015.

5.

JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia.

Li J, Spensberger D, Ahn JS, Anand S, Beer PA, Ghevaert C, Chen E, Forrai A, Scott LM, Ferreira R, Campbell PJ, Watson SP, Liu P, Erber WN, Huntly BJ, Ottersbach K, Green AR.

Blood. 2010 Sep 2;116(9):1528-38. doi: 10.1182/blood-2009-12-259747. Epub 2010 May 20.

6.

Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice.

Marty C, Lacout C, Martin A, Hasan S, Jacquot S, Birling MC, Vainchenker W, Villeval JL.

Blood. 2010 Aug 5;116(5):783-7. doi: 10.1182/blood-2009-12-257063. Epub 2010 May 14.

7.

Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia.

Hoelbl A, Schuster C, Kovacic B, Zhu B, Wickre M, Hoelzl MA, Fajmann S, Grebien F, Warsch W, Stengl G, Hennighausen L, Poli V, Beug H, Moriggl R, Sexl V.

EMBO Mol Med. 2010 Mar;2(3):98-110. doi: 10.1002/emmm.201000062.

8.

Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease.

Akada H, Yan D, Zou H, Fiering S, Hutchison RE, Mohi MG.

Blood. 2010 Apr 29;115(17):3589-97. doi: 10.1182/blood-2009-04-215848. Epub 2010 Mar 2.

9.

STAT5 activation is critical for the transformation mediated by myeloproliferative disorder-associated JAK2 V617F mutant.

Funakoshi-Tago M, Tago K, Abe M, Sonoda Y, Kasahara T.

J Biol Chem. 2010 Feb 19;285(8):5296-307. doi: 10.1074/jbc.M109.040733. Epub 2009 Dec 22.

10.

Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.

Santos FP, Kantarjian HM, Jain N, Manshouri T, Thomas DA, Garcia-Manero G, Kennedy D, Estrov Z, Cortes J, Verstovsek S.

Blood. 2010 Feb 11;115(6):1131-6. doi: 10.1182/blood-2009-10-246363. Epub 2009 Dec 11.

11.

Conditional deletion of STAT5 in adult mouse hematopoietic stem cells causes loss of quiescence and permits efficient nonablative stem cell replacement.

Wang Z, Li G, Tse W, Bunting KD.

Blood. 2009 May 14;113(20):4856-65. doi: 10.1182/blood-2008-09-181107. Epub 2009 Mar 3.

12.

Translation of the Philadelphia chromosome into therapy for CML.

Druker BJ.

Blood. 2008 Dec 15;112(13):4808-17. doi: 10.1182/blood-2008-07-077958. Review.

13.

Myeloproliferative disorders.

Levine RL, Gilliland DG.

Blood. 2008 Sep 15;112(6):2190-8. doi: 10.1182/blood-2008-03-077966. Review.

14.

Hematopoietic-specific Stat5-null mice display microcytic hypochromic anemia associated with reduced transferrin receptor gene expression.

Zhu BM, McLaughlin SK, Na R, Liu J, Cui Y, Martin C, Kimura A, Robinson GW, Andrews NC, Hennighausen L.

Blood. 2008 Sep 1;112(5):2071-80. doi: 10.1182/blood-2007-12-127480. Epub 2008 Jun 13.

15.

Targeting Ras in myeloid leukemias.

Braun BS, Shannon K.

Clin Cancer Res. 2008 Apr 15;14(8):2249-52. doi: 10.1158/1078-0432.CCR-07-1005. Review.

16.

Elucidation of the phenotypic, functional, and molecular topography of a myeloerythroid progenitor cell hierarchy.

Pronk CJ, Rossi DJ, MÃ¥nsson R, Attema JL, Norddahl GL, Chan CK, Sigvardsson M, Weissman IL, Bryder D.

Cell Stem Cell. 2007 Oct 11;1(4):428-42. doi: 10.1016/j.stem.2007.07.005.

17.

Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice.

Xing S, Wanting TH, Zhao W, Ma J, Wang S, Xu X, Li Q, Fu X, Xu M, Zhao ZJ.

Blood. 2008 May 15;111(10):5109-17. doi: 10.1182/blood-2007-05-091579. Epub 2008 Mar 11.

18.

Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice.

Tiedt R, Hao-Shen H, Sobas MA, Looser R, Dirnhofer S, Schwaller J, Skoda RC.

Blood. 2008 Apr 15;111(8):3931-40. Epub 2007 Dec 26.

19.

Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F.

Shide K, Shimoda HK, Kumano T, Karube K, Kameda T, Takenaka K, Oku S, Abe H, Katayose KS, Kubuki Y, Kusumoto K, Hasuike S, Tahara Y, Nagata K, Matsuda T, Ohshima K, Harada M, Shimoda K.

Leukemia. 2008 Jan;22(1):87-95. Epub 2007 Nov 22.

PMID:
18033315
20.

Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.

Zaleskas VM, Krause DS, Lazarides K, Patel N, Hu Y, Li S, Van Etten RA.

PLoS One. 2006 Dec 20;1:e18.

Supplemental Content

Support Center